Mineralys Therapeutics lists proposed common stock sales
Mineralys Therapeutics filed a Form 144 reporting proposed transactions in its common stock.
Rhea-AI Filing Summary
Mineralys Therapeutics filed a Form 144 reporting proposed transactions in its common stock. The filing lists a broker-assisted cashless exercise of 417 shares on 03/17/2026 and a series of prior dispositions by David Rodman during Q1 2026, including a 192,715-share sale on 01/05/2026 for $6,749,100.06. The entries are presented as notices of securities to be sold and past sales by an affiliate.
Positive
- None.
Negative
- None.
Insights
Form 144 lists a small exercise and multiple past sales by a reporting person.
The filing documents a broker-assisted cashless exercise of 417 shares on 03/17/2026 and multiple dispositions by David Rodman across January–March 2026, with the largest shown sale of 192,715 shares on 01/05/2026 for $6,749,100.06.
These entries are regulatory notices of proposed or recent sales; trading timing and further cash‑flow details follow standard Form 144 reporting procedures and may be reflected in subsequent ownership disclosures.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Mineralys (MLYS) Form 144 report?
Does the filing show an exercise of stock options for Mineralys?
Are the sale proceeds disclosed for the transactions?
AI-generated analysis. How Rhea-AI works. Not financial advice.